ангиотензин II 作为固体器官移植中外科期间低血压的血管压缩剂
Scott T Benken1, Riya Thomas1, Dustin R Fraidenburg2
1Department of Pharmacy Practice, University of Illinois Chicago College of Pharmacy, Chicago, IL 60612, USA.
Biomedicines
|August 29, 2024
概括
合成血管激素II (AT2S) 可能为患有低血压的移植患者提供更安全的血管压缩剂选择. 与传统的甲醇胺不同,AT2S可以改善全移植功能,减少心律失常等不良事件.
科学领域:
- 移植医学 移植医学
- 心血管药理学心血管药理学
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 在移植患者中,由于麻醉,手术压力和液体转移,外科手术期间的低血压是常见的.
- 传统的血管压缩剂,如甲基荷胺,可以引起心律失常,并可能对全移植功能产生负面影响.
- 需要血管压缩剂,有效地控制低血压,同时支持全移植健康并最大限度地减少不良事件.
研究的目的:
- 评估合成血管新生II (AT2S) 作为移植患者血管压缩剂的潜力.
- 探索AT2S在恢复氨酸-氨酸-氨系统及其血液动力学影响方面的独特作用机制.
- 评估AT2S在各种移植群体中的安全性和有效性.
主要方法:
- 审查现有文献,包括案例报告,试点研究和小系列.
- 分析AT2S的生理和血液动力学影响.
- 在移植的背景下,AT2S与传统的甲醇胺血管压缩剂的比较.
主要成果:
- 合成 ангиотензин II (AT2S) 作为一种 ангиотензин受体激动剂,重新平衡氨酸- ангиотензин- 氨系统.
- AT2S显示 afferent和efferent动脉的平衡血管收缩,可能有利于移植.
- 初步数据表明,AT2S在,肝,心脏和肺移植人群中是安全的,与β-上腺激动剂相比,心律失常的风险较低.
结论:
- 合成 ангиотензин II (AT2S) 是一种有前途的替代性血管压缩剂,用于治疗移植受体的外科手术期间低血压.
- 它的独特机制和改善全移植功能和减少不良事件的潜力需要进一步调查.
- 在等待进一步的研究的情况下,AT2S可能会成为移植医学中更广泛使用的药物.
相关概念视频
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
510
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
510
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
614
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
614
01:25Antihypertensive Drugs: Direct Renin Inhibitors
511
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
511
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
404
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
404
01:33Hormonal Regulation
33.0K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
33.0K
01:22Heart Failure Drugs: Diuretics
352
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
352